These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 14757005)

  • 1. [Primary HIV drug resistance in a prison population. REPRICOVA-2 Study].
    García-Guerrero J; Herrero A; Bedia M; Araújo R; Castellano JC;
    Enferm Infecc Microbiol Clin; 2004 Jan; 22(1):29-31. PubMed ID: 14757005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 Drug Resistance Profiles for the HIV Protease and Reverse Transcriptase Gene in Patients Receiving Combination Therapy in Tehran, Iran.
    Sadeghi L; Lolaie M; Tabatabai RA; Bayanolhagh S; Taj L; Ahmadi NE; Abedinzadeh N; Vakili F; Ahmadi G; Mohraz M
    Infect Disord Drug Targets; 2018; 18(3):241-248. PubMed ID: 29663899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New trends of primary drug resistance among HIV type 1-infected men who have sex with men in Liaoning Province, China.
    Zhao B; Han X; Dai D; Liu J; Ding H; Xu J; Chu Z; Bice T; Diao Y; Shang H
    AIDS Res Hum Retroviruses; 2011 Oct; 27(10):1047-53. PubMed ID: 21417755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of HIV-1 drug resistance mutations among Spanish prison inmates.
    García-Guerrero J; Sáiz de la Hoya P; Portilla J; Marco A; Sánchez-Payá J; Moreno S;
    Eur J Clin Microbiol Infect Dis; 2006 Nov; 25(11):695-701. PubMed ID: 17043836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes.
    Simen BB; Simons JF; Hullsiek KH; Novak RM; Macarthur RD; Baxter JD; Huang C; Lubeski C; Turenchalk GS; Braverman MS; Desany B; Rothberg JM; Egholm M; Kozal MJ;
    J Infect Dis; 2009 Mar; 199(5):693-701. PubMed ID: 19210162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High rate of resistance to antiretroviral drugs among HIV-infected prison inmates.
    Gallego O; Corral A; De Mendoza C; Gonzalez-Lahoz J; Soriano V
    Med Sci Monit; 2003 Jun; 9(6):CR217-21. PubMed ID: 12824949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiretroviral resistance in individuals presenting therapeutic failure and subtypes of the human immunodeficiency virus type 1 in the Northeast Region of Brazil.
    Cavalcanti AM; Lacerda HR; Brito AM; Pereira S; Medeiros D; Oliveira S
    Mem Inst Oswaldo Cruz; 2007 Nov; 102(7):785-92. PubMed ID: 17992369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diversity of HIV-1 genotypes and high prevalence of pretreatment drug resistance in newly diagnosed HIV-infected patients in Shanghai, China.
    Wang Z; Zhang M; Zhang R; Liu L; Shen Y; Wang J; Lu H
    BMC Infect Dis; 2019 Apr; 19(1):313. PubMed ID: 30961560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of drug-resistant and nonsubtype B HIV strains in antiretroviral-naïve, HIV-infected individuals in New York State.
    Parker MM; Gordon D; Reilly A; Horowitz HW; Waters M; Bennett R; Hallack R; Smith J; Lamson D; Aydemir A; Dvali N; Agins BD; Drusano GL; Taylor J;
    AIDS Patient Care STDS; 2007 Sep; 21(9):644-52. PubMed ID: 17919091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Puthanakit T; Jourdain G; Hongsiriwon S; Suntarattiwong P; Chokephaibulkit K; Sirisanthana V; Kosalaraksa P; Petdachai W; Hansudewechakul R; Siangphoe U; Suwanlerk T; Ananworanich J;
    HIV Med; 2010 Oct; 11(9):565-72. PubMed ID: 20345882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prevalence of resistance to antiretroviral drugs in Spain].
    Larrú Martínez B; de José MI; Bellón JM; Gurbindo MD; León JA; Ciria L; Ramos JT; Mellado MJ; Pocheville I; Jiménez JL; Muñoz-Fernández M
    An Pediatr (Barc); 2007 Aug; 67(2):104-8. PubMed ID: 17692254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretroviral treatment outcome following genotyping in Thai children who failed dual nucleoside reverse transcriptase inhibitors.
    Bunupuradah T; Suntarattiwong P; Li A; Sirivichayakul S; Pancharoen C; Boonrak P; Puthanakit T; Kerr SJ; Ruxrungtham K; Chotpitayasunondh T; Hirschel B; Ananworanich J;
    Int J Infect Dis; 2010 Apr; 14(4):e311-6. PubMed ID: 19699673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of HIV-1 transmitted drug resistance in recently infected, treatment-naïve persons in the Southwest of Iran, 2014-2015.
    Ghafari S; Memarnejadian A; Samarbaf-Zadeh A; Mostafavi E; Makvandi M; Salmanzadeh S; Ghadiri A; Jordan MR; Mousavi E; Jahanbakhsh F; Azadmanesh K
    Arch Virol; 2017 Sep; 162(9):2737-2745. PubMed ID: 28589513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brazilian Network for HIV Drug Resistance Surveillance (HIV-BResNet): a survey of chronically infected individuals.
    Brindeiro RM; Diaz RS; Sabino EC; Morgado MG; Pires IL; Brigido L; Dantas MC; Barreira D; Teixeira PR; Tanuri A;
    AIDS; 2003 May; 17(7):1063-9. PubMed ID: 12700457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited evolution but increasing trends of primary non-nucleoside reverse transcriptase inhibitor resistance mutations in therapy-naive HIV-1-infected individuals in India.
    Neogi U; Gupta S; Palchaudhuri R; Rao SD; Shastri S; Diwan V; Laishram RS; De Costa A; Shet A
    Antivir Ther; 2014; 19(8):813-8. PubMed ID: 24699043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227.
    Ruxrungtham K; Pedro RJ; Latiff GH; Conradie F; Domingo P; Lupo S; Pumpradit W; Vingerhoets JH; Peeters M; Peeters I; Kakuda TN; De Smedt G; Woodfall B;
    HIV Med; 2008 Nov; 9(10):883-96. PubMed ID: 18795960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug Resistance-Associated Mutations in Antiretroviral Treatment-Experienced Patients in Kuwait.
    Chehadeh W; Albaksami O; John SE; Al-Nakib W
    Med Princ Pract; 2018; 27(2):152-157. PubMed ID: 29506011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prevalence of antiretroviral drug resistance in treatment-naive injecting drug users infected with HIV-1 in Guangzhou, 2008-2015].
    Xu LQ; Han ZG; Zhang YL; Wu H; Gao K; Li QM; Xu HF; Cai YS; Xia Y
    Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Feb; 40(2):196-201. PubMed ID: 30744272
    [No Abstract]   [Full Text] [Related]  

  • 20. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
    Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
    Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.